PDVAC Agenda 2020: An update on Tuberculosis vaccine development activities
Virtual Consultation 6, 3 September 2020
Overview
2020 WHO Product Development for Vaccines Advisory Committee (PDVAC) Virtual Consultation 6: An update on Tuberculosis vaccine development activities: 3 September 2020
CHAIR: David Kaslow
A TB vaccine roadmap has been drafted by the Amsterdam Institute of Global Health and Development, with funding from The European Developing Countries Clinical Trials partnership (EDCTP,) and extensive TB vaccine epidemiological and economic modelling is being carried out by the LSHTM and global partners, including a WHO-funded ‘Full Value Assessment of TB Vaccines’ project, and a BMGF-funded M72/AS01 and BCG-revaccination specific modelling project.
Within this context, the objectives of this PDVAC meeting on TB are to:
- Understand the current status, future plans and critical issues related to the M72/AS01 product development plan and the potential BCG revaccinations strategy;
- Review the proposed workstreams of the TB vaccine roadmap development and assess how they align with progressing the 3 WHO TB vaccine development goals;
- Introduce the ongoing WHO-funded Full Value Assessment of TB Vaccines project and assess how this progresses the WHO’s Full Value of Vaccines Assessment approach, and what if any, high priority follow-up work is advised
- Introduce the ongoing BMGF-funded M72/AS01 and BCG revaccination specific modelling project, and advise if and how it could be more useful to global and country stakeholders
- Assess the immediate TB vaccine development related needs and priorities, from PDR/PDVAC